Description: eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR’s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR’s product candidates is designed to act on a single protein that drives the expression of multiple functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR’s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR’s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. In addition to the company’s oncology focus, zotatifin is being evaluated as a potential host-directed anti-viral therapy in patients with mild to moderate COVID-19 in collaboration with the University of California, San Francisco, under a $5 million grant sponsored by the Defense Advanced Research Projects Agency.
Home Page: effector.com
EFTR Technical Analysis
142 North Cedros Avenue
Solana Beach,
CA
92075
United States
Phone:
858 925 8215
Officers
| Name | Title |
|---|---|
| Dr. Stephen T. Worland Ph.D. | CEO, Pres & Director |
| Mr. Michael Byrnes M.B.A. | Chief Financial Officer |
| Dr. Siegfried Reich Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board |
| Dr. Douglas Warner M.D. | Chief Medical Officer |
| Dr. Mayank J. Gandhi M.D. | Chief Bus. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.408 |
| Price-to-Book MRQ: | 1.5445 |
| Price-to-Sales TTM: | 5.2547 |
| IPO Date: | 2021-08-26 |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |